Genmab A/S
http://www.genmab.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genmab A/S
Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.
EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody
If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.
Blow To Genmab As It Is Set To Lose Darzalex Royalties Sooner Than Hoped
The Danish firm will stop receiving royalties on Darzalex after 2030 having has lost on two issues heard at an arbitration tribunal, in a significant blow to its finances.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule